Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency

Journal of the American Society of Nephrology

Volumn 9, Issue 8, 1998, Pages 1482-1488

  Samuelsson, Ola ^a,c   Attman, Per Ola ^a   Knight Gibson, Carolyn ^b   Larsson, Rutger ^a   Mulec, Henrik ^a   Weiss, Lars ^a   Alaupovic, Petar ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B;

ARTICLE; CHRONIC KIDNEY FAILURE; DIAGNOSTIC VALUE; DYSLIPOPROTEINEMIA; FEMALE; HUMAN; KIDNEY FUNCTION; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 0031927416     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Attman P-O, Samuelsson O, Alaupovic P: Lipid metabolism and renal failure. Am J Kidney Dis 21: 573-592, 1993
2. Ma KW, Greene EL, Raij L: Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J Kidney Dis 19: 505-513, 1992
3. Keane WF, Kasiske BL, O'Donnell MP: Lipids and progressive glomerulosclerosis: A model analogous to atherosclerosis. Am J Nephrol 8: 261-271, 1988
4. Keane WF, O'Donnell MP, Kasiske BL, Schmitz PG: Lipids and the progression of renal disease. J Am Soc Nephrol 1 : S69-S74, 1990
5. Maschio G, Oldizzi L, Rugio C, DeBiase V, Loschiavo C: Effect of dietary manipulation on the lipid abnormalities in patients with chronic renal failure. Kidney Int 39[Suppl 31]: S70-S72, 1991
6. Cappelli P, Evangelista M, Bononini M, Palmieri PF, Albertazzi A: Lipids in the progression of chronic renal failure. Nephron 62: 31-35, 1992
7. Samuelsson O, Aurell M, Knight-Gibson C, Alaupovic P, Attman P-O: Apolipoprotein-B-containing lipoproteins and the progression of renal insufficiency. Nephron 63: 279-285, 1993
8. Mulec H, Johnson SA, Wiklund O, Björck S: Cholesterol: A renal risk factor in diabetic nephropathy. Am J Kidney Dis 22: 196-201, 1993
9. Krolewski A, Warram JH, Chriestlieb AR: Hypercholesterolemia: A determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int 45[Suppl 45]: S125-S131, 1995
10. Ravid M, Neuman L, Lishner M: Plasma lipids and the progression of nephropathy in diabetes mellitus type II: Effects of ACE inhibitors. Kidney Int 47: 907-910, 1995
11. Attman P-O, Knight-Gibson C, Tavella M, Samuelsson O, Alaupovic P: Increased concentrations of apo B-containing triglyceride-rich lipoprotein particles in patients with chronic renal failure. Miner Electrolyte Metab 18: 199-202, 1992
12. Cachera C, Kandoussi A, Equagoo K, Fruchart J-C, Tacquet A: Evaluation of apolipoprotein A-I containing particles in chronic renal failure patients undergoing hemodialysis. Am J Nephrol 10: 171-172, 1990
13. Samuelsson O, Mulec H, Knight-Gibson C, Attman P-O, Kron B, Larsson R, Weiss L, Alaupovic P: Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 12: 1908-1915, 1997
14. Jagenburg R, Attman P-O, Aurell M, Bucht H: Determination of glomerular filtration rate in advanced renal insufficiency. Scand J Urol Nephrol 12: 133-137, 1978
15. 1 values and apolipoprotein composition of the major lipoprotein density classes. Biochim Biophys Acta 920: 9-19, 1987
16. Warnick GR, Albers JJ: A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res 19: 65-76, 1978
17. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502, 1972
18. Curry MD, Alaupovic P, Suenram CA: Determination of apolipoprotein A and its constitutive AI and AII polypeptides by separate electroimmunoassays. Clin Chem 22: 315-322, 1976
19. Curry MD, Gustafson A, Alaupovic P, McConathy WJ: Electroimmunoassay, radioimmunoassay, and radial immunodiffusion assay evaluated for quantification of human apolipoprotein B. Clin Chem 24: 280-286, 1978
20. Curry MD, McConathy WJ, Fesmire JD, Alaupovic P: Quantitative determination of human apolipoprotein C-III by electroimmunoassay. Biochim Biophys Acta 617: 505-513, 1980
21. Curry MD, McConathy WJ, Alaupovic P, Ledford JD, Popovic M: Determination of human apolipoprotein E by electroimmunoassay. Biochim Biophys Acta 439: 413-425, 1976
22. Attman PO, Alaupovic P, Gustafson A: Serum apolipoprotein profile of patients with chronic renal failure. Kidney Int 32: 368-375, 1987
23. Parra HJ, Mezdour H, Ghalim N, Bard JM, Fruchart JC: Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates. Clin Chem 36: 1431-1435, 1990
24. Alaupovic P, Hodis HN, Knight-Gibson C, Mack WJ, LaBree L, Cashin-Hemphill L, Corder CN, Kramsch DM, Blankenhorn DH: Effects of lovastatin on apoA- and apoB-containing lipoprotein families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS). Arterioscler Thromb 14: 1906-1914, 1994
25. Alaupovic P: The significance of apolipoproteins for structure, function and classification of plasma lipoproteins. In: Methods in Enzymology: Plasma Lipoproteins, Part C, Quantitation, Vol. 263, edited by Bradley WA, Gianturco SH, Segrest JP, San Diego, Academic, 1996, pp 32-60
26. Alaupovic P: The lipoprotein family concept and its clinical significance. Nutr Metab Cardiovasc Dis 2: 52-54, 1992
27. Kamanna VS, Roh DD, Kirschenbaum MA: Atherogenic lipoproteins: Mediators of glomerular injury. Am J Nephrol 13: 1-15, 1993
28. Wheeler DC: Lipids: What is the evidence for their role in progressive renal disease? Nephrol Dial Tranplant 10: 14-16, 1995
29. Krauss RM: Relationship of intermediate and low-density lipoprotein subspecies to risk of coronary artery disease. Am Heart J 113: 578-582, 1987
30. Havel RJ: Role of triglyceride-rich lipoproteins in progression of atherosclerosis. Circulation 81: 694-696, 1990
31. Slyper AH: A fresh look at the atherogenic remnant hypothesis. Lancet 340: 289-291, 1992
32. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill L, Kramsch D, Blankenhorn DH: Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 90: 42-49, 1994
33. Alaupovic P, Knight-Gibson C, Hodis HN, Mack WJ, Cashin-Hemphill L, Blankenhorn DH: Effect of apoB-containing lipoprotein particles on the progression of atherosclerotic lesions in the Monitored Atherosclerosis Regression Study (MARS) [Abstract]. Atherosclerosis 109: 154, 1994
34. Brown JH, Hunt LP, Vites NP, Short CD, Gokal R, Mallick NP: Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant 9: 1136-1142, 1994
35. Stenvinkel P, Alvestrand A, Bergström J: Factors influencing progression in patients with chronic renal failure. J Intern Med 226: 183-188, 1989
36. Williams PS, Fass G, Bone JM: Renal pathology and proteinuria determine progression in untreated mild/moderate renal failure. Q J Med 67: 343-354, 1988
37. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek LW, Striker G: The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 330: 877-884, 1994
38. Warwick GL, Fox JG, Boulton-Jones J: The relationship between urinary albumin excretion rate and serum cholesterol in primary glomerular disease. Clin Nephrol 41: 135-137, 1994